A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of of VSA012 in Subjects with Paroxysmal Nocturnal Hemoglobinuria(PNH)

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

All Listed Sponsors

lead

Visirna Therapeutics HK Limited

INDUSTRY